Oral phosphodiesterase type 5 inhibitors alleviate recurrent priapism complicating thalassemia intermedia: A case report

Journal of Sexual Medicine

Volumn 6, Issue 7, 2009, Pages 2068-2071

  Tzortzis, Vassilios ^a   Mitrakas, Lampros ^a   Gravas, Stavros ^a   Mamoulakis, Charalampos ^b   Meissner, Andreas ^b   Kyriakou, Despina ^a   Melekos, Michael D ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Anemia intermedia; PDE5is; PDE5is for priapism; Reccurent priapism

Indexed keywords

ANTITHROMBOCYTIC AGENT; PHENYLEPHRINE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; PHOSPHODIESTERASE INHIBITOR;

ADULT; ARTICLE; BLOOD GAS ANALYSIS; BLOOD TRANSFUSION; CASE REPORT; DRUG EFFICACY; GENERAL CONDITION IMPROVEMENT; HUMAN; HYPERSPLENISM; LONG TERM CARE; LOW DRUG DOSE; MALE; MORNING DOSAGE; PAINFUL ERECTION; PATIENT SATISFACTION; PRIAPISM; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; SPLENECTOMY; THALASSEMIA; THALASSEMIA INTERMEDIA; UNSPECIFIED SIDE EFFECT; ANEMIA; BETA THALASSEMIA; COMPLICATION; DELTA THALASSEMIA; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; SECONDARY PREVENTION;

ADMINISTRATION, ORAL; ADULT; ANEMIA; BETA-THALASSEMIA; DELTA-THALASSEMIA; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; PRIAPISM; SECONDARY PREVENTION; SPLENECTOMY;

EID: 67649887608     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01285.x     Document Type: Article

References (13)

1. Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: Revisited. Blood Cells Mol Dis 2006;37:12-20.
2. Jackson N, Franklin IM, Hughes MA. Recurrent priapism following splenectomy for thalassaemia intermedia. Br J Surg 1986;73:678.
3. Rao KR, Patel AR. Priapism and thalassaemia intermedia. Br J Surg 1986;73:1048.
4. Macchia P, Massei F, Nardi M, Favre C, Brunori E, Barba V. Thalassemia intermedia and recurrent priapism following splenectomy. Haematologica 1990;75:486-7.
5. Dore F, Bonfigli S, Pardini S, Pirozzi F, Longinotti M. Priapism in thalassemia intermedia. Haematologica 1991;76:523.
6. Burnett AL. Pathophysiology of priapism: Dysregulatory erection physiology thesis. J Urol 2003;170:26-34.
7. Bialecki ES, Bridges KR. Sildenafil relieves priapism in patients with sickle cell disease. Am J Med 2002;113:252.
8. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med 2006;3:1077-84.
9. Ramos CE, Park JS, Ritchey ML, Benson GS. High flow priapism associated with sickle cell disease. J Urol 1995;153:1619-21.
10. Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis associated priapism in sickle cell disease. Blood 2005;106:3264-7.
11. Mostafa T. Oral phosphodiesterase type 5 inhibitors: Nonerectogenic beneficial uses. J Sex Med 2008;5:2502-18.
12. Burnett AL, Bivalacqua TJ. Glucose-6-phosphate dehydrogenase deficiency: An etiology for idiopathic priapism? J Sex Med 2008;5:237-40.
13. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP. Pulmonory hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-95.